BankPlus Wealth Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

BankPlus Wealth Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$356K	Buy	+30,458	New	+$498K	0.16%	89

Other funds holding MLTX

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

BankPlus Wealth Management's MLTX Position: Q3 2026 in Review

BankPlus Wealth Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 30,458 shares worth $356K. The stake represents 0.16% of the portfolio and ranks #89 among its holdings.

14 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

BankPlus Wealth Management held 30,458 shares of MoonLake Immunotherapeutics worth $356K as of Q3 2026.
MoonLake Immunotherapeutics was a new BankPlus Wealth Management position in Q3 2026.
MoonLake Immunotherapeutics made up 0.16% of BankPlus Wealth Management's portfolio in Q3 2026, its #89 holding.
14 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on BankPlus Wealth Management's 13F filing for Q3 2026, filed 13 Oct 2026.